Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 4 (2007), Issue 5 (May)

1. Sex differences in lung cancer survival: do tumors behave differently in elderly women?
   J Clin Oncol, 25(13): 1705-12. [Abstract] [Full-text]
2. A risk model for prediction of lung cancer.
   J Natl Cancer Inst, 99(9): 715-26. [Abstract] [Full-text]
3. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
   Oncologist, 12(4): 451-64. [Abstract] [Full-text]
4. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
   J Clin Oncol, 25(13): 1698-704. [Abstract] [Full-text]
5. Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718.
   J Thorac Oncol, 2(5): 440-4. [Abstract] [Full-text]
6. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.
   J Thorac Oncol, 2(5): 430-9. [Abstract] [Full-text]
7. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
   J Thorac Oncol, 2(5): 423-9. [Abstract] [Full-text]
8. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib.
   J Thorac Oncol, 2(5): 414-22. [Abstract] [Full-text]
9. Prognostic factors in 3315 completely resected cases of clinical stage I non-small cell lung cancer in Japan.
   J Thorac Oncol, 2(5): 408-13. [Abstract] [Full-text]
10. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials.
    J Thorac Oncol, 2(5): 402-7. [Abstract] [Full-text]
11. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
    J Thorac Oncol, 2(5): 397-401. [Abstract] [Full-text]
12. An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): maximizing the diagnostic procedure and the use of low-volume lung biopsies.
    J Thorac Oncol, 2(5): 387-96. [Abstract] [Full-text]
13. The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer.
    J Thorac Oncol, 2(5): 377-83. [Abstract] [Full-text]
14. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
    Clin Cancer Res, 13(9): 2795-803. [Abstract] [Full-text]
15. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
    Clin Cancer Res, 13(9): 2684-91. [Abstract] [Full-text]
16. Expression of a peroxisome proliferator-activated receptor gamma 1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress.
    Clin Cancer Res, 13(9): 2577-83. [Abstract] [Full-text]
17. Cells, cells, and more cells.
    Surv Ophthalmol, 52(3): 315-24. [Abstract] [Full-text]
18. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer.
    J Clin Invest, 117(5): 1294-304. [Abstract] [Full-text]
19. Geranylgeranyltransferase I as a target for anti-cancer drugs.
    J Clin Invest, 117(5): 1223-5. [Abstract] [Full-text]
20. Postacquisition detection of tumor motion in the lung and upper abdomen using list-mode PET data: a feasibility study.
    J Nucl Med, 48(5): 758-63. [Abstract] [Full-text]
21. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT.
    J Nucl Med, 48(5): 744-51. [Abstract] [Full-text]
22. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.
    J Clin Invest, 117(5): 1305-13. [Abstract] [Full-text]
23. Application of genomic biomarkers to predict increased lung tumor incidence in 2-year rodent cancer bioassays.
    Toxicol Sci, 97(1): 55-64. [Abstract] [Full-text]
24. The role of STATs in lung carcinogenesis: an emerging target for novel therapeutics.
    J Mol Med, 85(5): 427-36. [Abstract] [Full-text]
25. Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.
    Cancer Res, 67(9): 4425-33. [Abstract] [Full-text]
26. Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1).
    Cancer Res, 67(9): 4382-9. [Abstract] [Full-text]
27. Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells.
    Cancer Res, 67(9): 4236-43. [Abstract] [Full-text]
28. Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis.
    Cancer Res, 67(9): 4113-22. [Abstract] [Full-text]
29. Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung.
    J Clin Endocrinol Metab, 92(5): 1600-5. [Abstract] [Full-text]
30. Genome-wide single nucleotide polymorphism analysis of lung cancer risk detects the KLF6 gene.
    Cancer Lett, 251(2): 311-6. [Abstract] [Full-text]
31. Management of non-retroperitoneal residual germ cell tumor masses.
    Urol Clin North Am, 34(2): 235-43; abstract x. [Abstract] [Full-text]
32. Lung cancer in the elderly.
    J Clin Oncol, 25(14): 1898-907. [Abstract] [Full-text]
33. Adjuvant therapy in the elderly: making the right decision.
    J Clin Oncol, 25(14): 1870-5. [Abstract] [Full-text]
34. Primary cardiac fibrosarcoma with pulmonary metastasis in a Labrador Retriever.
    Vet Pathol, 44(3): 403-7. [Abstract] [Full-text]
35. Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma.
    Histopathology, 50(6): 720-6. [Abstract] [Full-text]
36. Correlation between EGFR gene mutation pattern and Akt phosphorylation in pulmonary adenocarcinomas.
    Pathol Int, 57(5): 268-75. [Abstract] [Full-text]
37. Epidermal growth factor receptor mutations in lung cancers.
    Pathol Int, 57(5): 233-44. [Abstract] [Full-text]
38. Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.
    Expert Rev Anticancer Ther, 7(5): 635-40. [Abstract] [Full-text]
39. Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol, 60(2): 267-74. [Abstract] [Full-text]
40. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol, 60(2): 211-8. [Abstract] [Full-text]
41. Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy.
    Cancer Chemother Pharmacol, 60(2): 189-95. [Abstract] [Full-text]
42. Noncrystallized form of immunoglobulin-storing histiocytosis as a cause of chronic lung infiltration in multiple myeloma.
    Ann Diagn Pathol, 11(3): 220-2. [Abstract] [Full-text]
43. A haplotype encompassing the variant allele of DNA repair gene polymorphism ERCC2/XPD Lys751Gln but not the variant allele of Asp312Asn is associated with risk of lung cancer in a northeastern Chinese population.
    Cancer Genet Cytogenet, 175(1): 47-51. [Abstract] [Full-text]
44. From the Archives of the AFIP: pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.
    Radiographics, 27(3): 867-82. [Abstract] [Full-text]
45. Cardiac metastasis from lung adenocarcinoma causing atrioventricular block and left ventricular outflow tract obstruction.
    Chest, 131(5): 1569-72. [Abstract] [Full-text]
46. A novel technique for localization of small pulmonary nodules.
    Chest, 131(5): 1526-31. [Abstract] [Full-text]
47. Solid or partly solid solitary pulmonary nodules: their characterization using contrast wash-in and morphologic features at helical CT.
    Chest, 131(5): 1516-25. [Abstract] [Full-text]
48. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans.
    Chest, 131(5): 1282-8. [Abstract] [Full-text]
49. Racial differences in cancer risk among relatives of patients with early onset lung cancer.
    Chest, 131(5): 1289-94. [Abstract] [Full-text]
50. Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer.
    Int J Radiat Oncol Biol Phys, 68(2): 531-40. [Abstract] [Full-text]
51. Reduction of normal lung irradiation in locally advanced non-small-cell lung cancer patients, using ventilation images for functional avoidance.
    Int J Radiat Oncol Biol Phys, 68(2): 562-71. [Abstract] [Full-text]
52. Kilo-voltage cone-beam computed tomography setup measurements for lung cancer patients; first clinical results and comparison with electronic portal-imaging device.
    Int J Radiat Oncol Biol Phys, 68(2): 555-61. [Abstract] [Full-text]
53. Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber. Effect on tumor metastasis and neutrophil recruitment.
    J Biol Chem, 282(20): 14984-91. [Abstract] [Full-text]
54. Interinstitutional variations in planning for stereotactic body radiation therapy for lung cancer.
    Int J Radiat Oncol Biol Phys, 68(2): 416-25. [Abstract] [Full-text]
55. Pulmonary manifestations in patients with cutaneous T-cell lymphomas.
    Cancer, 109(8): 1550-5. [Abstract] [Full-text]
56. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain.
    Cancer, 109(8): 1668-75. [Abstract] [Full-text]
57. Influence of interfraction interval on local tumor control in patients with limited-disease small-cell lung cancer treated with radiochemotherapy.
    Int J Radiat Oncol Biol Phys, 68(2): 426-32. [Abstract] [Full-text]
58. PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumors.
    Oncogene, 26(21): 3020-6. [Abstract] [Full-text]
59. Tumors in mice transgenic for the envelope protein of Jaagsiekte sheep retrovirus.
    Virus Genes, 35(1): 73-80. [Abstract] [Full-text]
60. The relevance of surgical therapy for bilateral and/or multiple pulmonary metastases in children.
    Eur J Pediatr Surg, 17(2): 84-9. [Abstract] [Full-text]
61. Bronchioloalveolar carcinoma arising in a congenital pulmonary airway malformation in a child: case report with an update of this association.
    J Pediatr Surg, 42(5): E1-4. [Abstract] [Full-text]
62. How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer.
    Br J Cancer, 96(10): 1498-503. [Abstract] [Full-text]
63. The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo.
    Br J Cancer, 96(10): 1532-9. [Abstract] [Full-text]
64. Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma.
    Br J Cancer, 96(10): 1569-78. [Abstract] [Full-text]
65. NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo.
    Cancer Immunol Immunother, 56(8): 1153-61. [Abstract] [Full-text]
66. Achaete-scute homolog-1 linked to remodeling and preneoplasia of pulmonary epithelium.
    Lab Invest, 87(6): 527-39. [Abstract] [Full-text]
67. Pulmonary metastasis of giant cell tumor of the bone diagnosed by fine-needle aspiration biopsy.
    Diagn Cytopathol, 35(6): 358-62. [Abstract] [Full-text]
68. Impact of smoking and smoking cessation on lung cancer mortality in the Asia-Pacific region.
    Am J Epidemiol, 165(11): 1280-6. [Abstract] [Full-text]
69. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Cancer Res, 67(10): 4981-8. [Abstract] [Full-text]
70. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
    Cancer Res, 67(10): 4933-9. [Abstract] [Full-text]
71. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2.
    Cancer Res, 67(10): 4851-9. [Abstract] [Full-text]
72. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells.
    Cancer Res, 67(10): 4827-33. [Abstract] [Full-text]
73. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity.
    Cancer Res, 67(10): 4665-70. [Abstract] [Full-text]
74. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers.
    Cancer Res, 67(10): 4638-47. [Abstract] [Full-text]
75. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
    Mol Cancer Res, 5(5): 509-20. [Abstract] [Full-text]
76. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
    Science, 316(5827): 1039-43. [Abstract] [Full-text]
77. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
    J Clin Oncol, 25(15): 2086-92. [Abstract] [Full-text]
78. The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers.
    J Pathol, 212(2): 170-9. [Abstract] [Full-text]
79. Biological and prognostic role of acid cysteine proteinase inhibitor (ACPI, cystatin A) in non-small-cell lung cancer.
    J Clin Pathol, 60(5): 515-9. [Abstract] [Full-text]
80. Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancer.
    J Clin Pathol, 60(5): 483-6. [Abstract] [Full-text]
81. Meat and fish consumption and risk of lung cancer: A case-control study in Galicia, Spain.
    Cancer Lett, 252(1): 115-22. [Abstract] [Full-text]
82. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?
    Cancer Treat Rev, 33(4): 391-406. [Abstract] [Full-text]
83. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase.
    Mol Pharmacol, 71(6): 1715-20. [Abstract] [Full-text]
84. Loss of heterozygosity and human telomerase reverse transcriptase (hTERT) expression in bronchial mucosa of heavy smokers.
    Cancer, 109(11): 2299-307. [Abstract] [Full-text]
85. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.
    Cancer, 109(9): 1836-44. [Abstract] [Full-text]
86. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer.
    Cancer, 109(9): 1829-35. [Abstract] [Full-text]
87. Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer.
    Cancer, 109(9): 1845-950. [Abstract] [Full-text]
88. Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy.
    Cancer, 109(9): 1821-8. [Abstract] [Full-text]
89. Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.
    Blood, 109(11): 4865-76. [Abstract] [Full-text]
90. Trends in lung cancer among young European women: the rising epidemic in France and Spain.
    Int J Cancer, 121(2): 462-5. [Abstract] [Full-text]
91. Molecular alterations in atypical adenomatous hyperplasia occurring in benign and cancer-bearing lungs.
    Diagn Mol Pathol, 16(2): 87-90. [Abstract] [Full-text]
92. Transxiphoid hand-assisted videothoracoscopic surgery.
    Ann Thorac Surg, 83(6): 1978-84. [Abstract] [Full-text]
93. Surgical techniques and results for partial or circumferential sleeve resection of the pulmonary artery for patients with non-small cell lung cancer.
    Ann Thorac Surg, 83(6): 1971-6; discussion 1976-7. [Abstract] [Full-text]
94. Video-assisted thoracoscopic surgery is more favorable than thoracotomy for resection of clinical stage I non-small cell lung cancer.
    Ann Thorac Surg, 83(6): 1965-70. [Abstract] [Full-text]
95. Deletion of a single allele of Cx43 is associated with a reduction in the gap junctional intercellular communication and increased cell proliferation of mouse lung pneumocytes type II.
    Cell Prolif, 40(3): 411-21. [Abstract] [Full-text]
96. Time factor in radiotherapy and chemotherapy for limited disease small-cell lung cancer.
    Cancer Invest, 25(3): 163-71. [Abstract] [Full-text]
97. Impact of elastic staining on the staging of peripheral lung cancers.
    Am J Surg Pathol, 31(6): 953-6. [Abstract] [Full-text]
98. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
    BMC Cancer, 7: 74. [Abstract] [Full-text]
99. Epigenomics in respiratory epithelium carcinogenesis: prevention and therapeutic challenges.
    Cancer Treat Rev, 33(3): 284-8. [Abstract] [Full-text]
100. Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas.
     J Thorac Cardiovasc Surg, 133(6): 1448-54. [Abstract] [Full-text]
101. Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer.
     J Thorac Cardiovasc Surg, 133(6): 1419-27. [Abstract] [Full-text]
102. Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.
     Br J Cancer, 96(11): 1644-9. [Abstract] [Full-text]
103. Integrative analysis and validation of robust gene signature in lung cancer.
     Biochem Biophys Res Commun, 358(3): 710-5. [Abstract] [Full-text]
104. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
     Biochem Pharmacol, 74(1): 41-53. [Abstract] [Full-text]
105. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol.
     BMC Cancer, 7: 77. [Abstract] [Full-text]
106. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
     J Clin Oncol, 25(16): 2256-61. [Abstract] [Full-text]
107. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
     J Clin Oncol, 25(16): 2248-55. [Abstract] [Full-text]
108. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer.
     J Clin Oncol, 25(16): 2243-7. [Abstract] [Full-text]
109. Sequence variations in DNA repair gene XPC is associated with lung cancer risk in a Chinese population: a case-control study.
     BMC Cancer, 7: 81. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.